The need for universal hepatitis B screening: Q&A with Kate Moraras on HepVu.org - please click here.

Liver Cancer Drug Watch

Compounds in Development for Liver Cancer

Updated Feb. 4, 2021

Drug Name 

Mechanism 

Company

Company Website

USA Status

Clinical Trial Website

Nexavar (Sorafenib) 

Raf/Mek/Erk inhibitor

Bayer

nexavar-us.com

Approved

N.A.

Stivarga (Regorafenib) 

Raf/kit/ret kinase inhibitor

Bayer

stivarga.com

Approved

N.A.

Opdivo (Nivolumab) 

PD1 inhibitor

Bristol Myers-Squibb

opdivo.com

Approved

N.A.

Opdivo (Nivolumab) + Yervoy (Ipilimumab) 

PD1 inhibitor/CTLA-4-blocking antibody

Bristol Myers-Squibb

bms.com

Approved

N.A.

Lenvima (Lenvatinib) 

VEGFR, PDGFR, FGFR, RET and c-Kit inhibitor

Eisai

lenvima.com

Approved

N.A.

Cabometyx (Cabozantinib) 

VEGFR2, c-MET, RET, KIT, FLT4, AXL inhibitor

Exelixis

cabometyx.com

Approved

N.A.

Tecentriq (Atezolizumab) + Avastin (Bevacizumab) 

PD-L1 monoclonal antibody/VEGFA inhibitor

Genentech

tecentriq.com

Approved

N.A.

Cyramza (Ramucirumab) 

VEGFR2 inhibitor

Eli Lilly and Co.

cyramza.com

Approved

N.A.

Imfinzi (Durvalumab) + Tremelimumab

PD-L1/CTLA-4 monoclonal antibody

AstraZeneca

astrazeneca.com

Phase II/III (phase II in combination with other drugs or procedures)

Clinical Trial

Cabozantinib + Opdivo (Nivolumab) ± Yervoy (Ipilimumab) 

MET inhibitor, PD1 inhibitor, CTLA-4-blocking antibody

Exelixis and Bristol-Myers Squibb

exelixis.com

Phase I/II

Clinical Trial

Cabozantinib + Tecentriq (Atezolizumab) vs. Nexavar (Sorafenib) 

MET inhibitor + PD-L1 monoclonal antibody vs. Raf/Mek/Erk inhibitor

Exelixis

exelixis.com

Phase III

Clinical Trial

Toripalamib + Lenvatinib

PD-1/VEGFR2, VEGFR3 antibody

Shanghai Junshi Bioscience Co.

junshi.com

Phase III

Clinical Trial

Nexavar (Sorafenib), as adjuvant 

Raf/Mek/Erk inhibitor

Bayer

nexavar.com

Phase II/III

Clinical Trial

Yiviva (YIV-906) + Sorafenib

Botanical

Yiviva Inc.

yiviva.com

Phase IIb

Clinical Trial

Milciclib

CDK2 Inhibitor

Tiziana Life Sciences

tizianalifesciences.com

Phase II

Clinical Trial

Galunisertib + Sorafenib

TGF-βR1/VEGFRs, C-KIT, PDGFRB, RAF inhibitor

Eli Lilly and Co.

lillytrials.com

Phase II

Clinical Trial

Tepotinib (MSC2156119J)

c-MET/HGF inhibitor

Merck KGaA, Darmstadt, Germany

emdgroup.com

Phase 1b/II

Clinical Trial

Galunisertib + Opdivo (Nivolumab)

TGF-βR1/PD-1 small molecular inhibitor

Eli Lilly and Co.

trials.lillytrialguide.com

Phase Ib/II

Clinical Trial

Spartalizumab +/- Capmatinib

PD-1/MET antibody

Novartis

novartis.com

Phase Ib/II

Clinical Trial

Pembrolizumab + Nexavar (Sorafenib)

PD-1/VEGFRs, C-KIT, PDGFRB, RAF inhibitor

Roswell Park Cancer Institute and Merck Sharpe & Dohme Corp.

roswellpark.org

Phase Ib/II

Clinical Trial

Pembrolizumab + Lenvima (Lenvatinib)

PD-1/VEGFR2, VEGFR3 antibody

Eisai

lenvima.com

Phase I/III

Clinical Trial

FGF401 +/- Spartalizumab

FGFR4 inhibitor/PD-1 antibody

Novartis, through a licensing agreement with EverNov, a subsidiary of Everest Medicines

everestmedicines.com

Phase I/II complete

Clinical Trial

Mogamulizumab + Opdivo (Nivolumab)

CCR4/PD-1 antibody

Kyowa Kirin Pharmaceutical Development, Inc. and Bristol-Myers Squibb

kyowakirin.com

Phase I/II

Clinical Trial

Pembrolizumab + Keytruda (Epacadostat)

PD-1/IDO1 antibody

Incyte Corporation

incyte.com

Phase I/II

Clinical Trial

Cabozantinib + Opdivo (Nivolumab)

MET inhibitor, VEGFRs/PD-1 antibody

Exelixis and Bristol-Myers Squibb

exelixis.com

Phase I/II

Clinical Trial (after resection)

Clinical Trial (with TACE)

XL888 + Pembrolizumab

Hsp90 inhibitor/PD-1 antibody

Merck Sharpe & Dohme Corp. and Exelixis

exelisis.com

Phase Ib

Clinical Trial 

Stivarga (Regorafenib) + Pembrolizumab

VEGFRs, FGFRs, C-KIT, PDGFRs, RAF/PD-1 antibody

Bayer and Merck Sharpe & Dohme Corp.

stivarga.com

Phase I

Clinical Trial

Avelumab + Axinitib

PD-L1/VEGFRs antibody, C-KIT, PDGFRs inhibitor

Pfizer

pfizer.com

Phase I

Clinical Trial 

Cyramza (Ramucirumab) + Imfinzi (Durvalumab)

VEGFR2/PD-L1 antibody

Eli Lilly and Co. and AstraZeneca

cyramza.com

Phase I

Clinical Trial